CompletedNCT00239356
Continuing aripiprazole after schizophrenia treatment studies
About this title
Read the official source — NCT00239356Medication studyAges 18–70Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 70 years.
What did participation involve?
The study group receives aripiprazole as a study medication.
- Listed locations
- Ottawa and 19 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMarch 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 119
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, Canada, United Kingdom, ...
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00239356
- Official title
Show the full official title
Aripiprazole (BMS-337039) for Outpatients With Schizophrenia Completing Aripiprazole Clinical Trials: A Non-Comparative Rollover Protocol
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Ottawa, Canada · Sherbrooke, Canada · Rijeka, Croatia
19 more locations
- Zagreb, Croatia
- Hradec Králové, Czechia
- Prague, Czechia
- Nantes Orvault, France
- Rennes, France
- Uzès, France
- Budapest, Hungary
- Győr, Hungary
- Vught, Netherlands
- Krakow, Poland
- Poznan, Poland
- Bucharest, Romania
- Saint Petersburg, Russia
- Westdene, South Africa
- Johannesburg, South Africa
- Cape Town, South Africa
- Antrim, United Kingdom
- Czechia
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
Listed age limits: 18 years to 70 years.
Want to explore more studies?
Explore studiesRelated studies
24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia